Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02071134
Recruitment Status : Recruiting
First Posted : February 25, 2014
Last Update Posted : January 16, 2019
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.

Condition or disease Intervention/treatment
Parkinson's Disease Device: Deep Brain Stimulation (DBS)

Detailed Description:

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.

Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Actual Study Start Date : February 2014
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Parkinson's disease
Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
Device: Deep Brain Stimulation (DBS)
Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Other Names:
  • Vercise DBS System
  • Boston Scientific




Primary Outcome Measures :
  1. Improvement in patient's quality of life (QoL) during the study as compared with baseline [ Time Frame: up to 3 years ]
    Change in quality of life assessments during the study as compared with baseline


Other Outcome Measures:
  1. Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline [ Time Frame: up to 3 years ]
    Change in patient's motor symptoms as determined by UPDRS during the study as compared with baseline

  2. Change in medication usage during the study as compared with baseline [ Time Frame: up to 3 years ]
  3. Impression of change scores during the study as compared with baseline [ Time Frame: 3 years ]
    Impression of change scores during the study as compared with baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with symptoms of Parkinson's disease that are not adequately controlled with medication
Criteria

Inclusion Criteria:

  • Meets criteria established in locally applicable Vercise System Direction for Use
  • At least 18 years old

Exclusion Criteria:

  • Meets any contraindication in the Vercise System locally applicable Directions for Use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02071134


Contacts
Layout table for location contacts
Contact: Diane Bowers Diane.bowers@bsci.com
Contact: Roshini Jain 469-766-9888 Roshini.Jain@bsci.com

Locations
Layout table for location information
United States, California
Boston Scientific Clinical Research Toll-Free Number Recruiting
Valencia, California, United States, 91355
Contact    855-213-9890    BSNClinicalTrials@bsci.com   
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Study Director: Roshini Jain Boston Scientific Neuromodulation Corporation

Additional Information:

Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT02071134     History of Changes
Other Study ID Numbers: A4010
First Posted: February 25, 2014    Key Record Dates
Last Update Posted: January 16, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Boston Scientific Corporation:
Deep brain stimulation
Parkinson's disease
Vercise

Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases